SHP Share Price

Open 4642.00 Change Price %
High 4669.50 1 Day 21.00 0.45
Low 4613.00 1 Week -193.00 -3.98
Close 4659.00 1 Month -260.50 -5.30
Volume 1263552 1 Year 723.00 18.37
52 Week High 5377.00
52 Week Low 2707.19
SHP Important Levels
Resistance 2 4711.38
Resistance 1 4689.79
Pivot 4647.17
Support 1 4628.21
Support 2 4606.62
LON UK Most Active Stocks
FRR 0.44 22.22%
CWC 74.60 0.27%
CWC 74.60 0.27%
CWC 74.60 0.27%
INC 0.04 -20.00%
NYO 0.06 0.00%
LLOY 68.27 0.95%
HER 0.12 0.00%
HER 0.12 0.00%
OTC 0.03 0.00%
LON UK Top Gainers Stocks
AKT 28.50 5177.78%
HHR 58.00 900.00%
MLD 10.00 700.00%
MES 0.28 75.00%
MES 0.28 75.00%
MES 0.28 75.00%
BAC 23.38 67.00%
BAC 23.38 67.00%
BAC 23.38 67.00%
PFLM 5.75 64.29%
LON UK Top Losers Stocks
ENDV 0.02 -99.85%
KEA 0.10 -91.30%
ACU 0.05 -87.50%
ACU 0.05 -87.50%
ACU 0.05 -87.50%
DCP 0.50 -75.61%
PCI 3.50 -53.27%
PCI 3.50 -53.27%
ALPH 0.06 -40.00%
BHR 0.02 -33.33%

Shire PLC (LON: SHP)

SHP Technical Analysis 3
As on 23rd Mar 2017 SHP Share Price closed @ 4659.00 and we RECOMMEND Sell for LONG-TERM with Stoploss of 4684.59 & Sell for SHORT-TERM with Stoploss of 4688.66 we also expect STOCK to react on Following IMPORTANT LEVELS.
SHP Target for March
1st Target up-side 5166.21
2nd Target up-side 5373.82
3rd Target up-side 5581.44
1st Target down-side 4573.79
2nd Target down-side 4366.18
3rd Target down-side 4158.56
SHP Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website
SHP Address
5 Riverwalk
Citywest Business Campus
Dublin, 24
Phone: 353 1 429 7700
SHP Latest News
Quick Review on Trend Indicator Levels: Shire PLC (SHP.L)   Rives Journal   - 23rd Mar 17
Here's Why You Should Buy Shire PLC (ADR) (NASDAQ:SHPG)   Library For Smart Investors   - 23rd Mar 17
Shire's SHP655 Fast Track'd for rare enzyme deficiency   Seeking Alpha   - 22nd Mar 17
Shire PLC 27.4% Potential Upside Indicated by Exane BNP Paribas   DirectorsTalk Interviews   - 22nd Mar 17
Why buying Shire plc NOW could be a smart move   Motley Fool UK   - 21st Mar 17
About: Shire PLC (SHPG)   Seeking Alpha   - 18th Mar 17
Expanded use of Shire's CINRYZE OK'd in Europe   Seeking Alpha   - 16th Mar 17
Shire PLC 40.5% Potential Upside Indicated by Goldman Sachs   DirectorsTalk Interviews   - 16th Mar 17
Shire plc (SHPG) Receives European Approval for Label Extension of CINRYZE®   - 16th Mar 17
Shire plc (SHPG) Ex-Dividend Date Scheduled for March 08, 2017   Nasdaq   - 07th Mar 17
Interactive Technical Analysis Chart Shire PLC ( SHP LON UK )
Java support must be enabled in order to display FnCharts.
You can download Java from
Your Comments and Response on Shire PLC
SHP Business Profile
Shire plc, a biopharmaceutical company, together with its subsidiaries, researches, develops, licenses, manufactures, markets, distributes, and sells pharmaceutical products. It offers various products for the treatment of attention deficit hyperactivity disorder (ADHD), including VYVANSE/VENVANSE, a pro-drug stimulant; ELVANSE/TYVENSE; INTUNIV, an alpha-2A receptor agonist; EQUASYM, a methylphenidate hydrochloride; and ADDERALL XR, an extended release treatment for ADHD. The company also provides PENTASA and LIALDA/MEZAVANT for ulcerative colitis treatment; and RESOLOR, a 5-HT4 receptor agonist for oral symptomatic treatment of chronic constipation in women. In addition, it offers FOSRENOL, a phosphate binder for use in end-stage renal disease receiving dialysis; and XAGRID for the reduction of elevated platelet counts in at-risk essential thrombocythemia patients, as well as for the treatment of thrombocythemia. Further, the company provides REPLAGAL for the treatment of Fabry disease; ELAPRASE for the treatment of hunter syndrome; VPRIV for the treatment of type 1 Gaucher disease; and FIRAZYR for the symptomatic treatment of acute attacks of hereditary angioedema. Additionally, it offers FOSRENOL for the treatment of hyperphosphatemia in end stage renal disease; XAGRID for the reduction of elevated platelet counts; and CINRYZE, a C1 esterase inhibitor therapy for routine prophylaxis against hereditary angioedema. The company also licenses its patented antiviral products for human immunodeficiency virus and hepatitis B virus. Shire plc markets its products directly to government hospitals, clinics, pharmacies, and other agencies; and through wholesalers and distributors. The company sells its products in North America, the United Kingdom, the Republic of Ireland, and internationally. Shire plc has research collaboration with Santaris Pharma A/S. The company was founded in 1986 and is headquartered in Dublin, Ireland.